TNF and cancer: In cancer patients, intraperitoneal/intravenous/subcutaneous administration of IL-12 increased peritoneal/serum levels of IFN-γ, TNF-α, IL-10, IL-8, VEGF, IP-10, and neopterin [34]–[37].